PERIoperative antibiotic prophylaxis in PANCreatic surgery (PeriPANC): protocol for a prospective observational study comparing antibiotic regimens and their impact on postoperative outcomes in pancreatic surgery
Introduction Despite advancements in pancreatic surgery, postoperative infections—particularly surgical site infections (SSIs), which occur in 6-17% of cases—continue to be a leading cause of morbidity. Effective perioperative antibiotic prophylaxis is essential, though the optimal regimen remains u...
Enregistré dans:
| Auteurs principaux: | , , , , , , , , , , , |
|---|---|
| Format: | Article (Journal) |
| Langue: | anglais |
| Publié: |
August 1, 2025
|
| In: |
BMJ open
Year: 2025, Volume: 15, Numéro: 7, Pages: 1-6 |
| ISSN: | 2044-6055 |
| DOI: | 10.1136/bmjopen-2025-103572 |
| Accès en ligne: | Verlag, kostenfrei, Volltext: https://doi.org/10.1136/bmjopen-2025-103572 Verlag, kostenfrei, Volltext: https://bmjopen.bmj.com/content/15/7/e103572 
|
| Notes sur l'auteur: | Sophie Weber, Niels Siegel, Thomas Hank, Darius Halm, Benedict Kinny-Köster, Max Heckler, Jonathan M. Harnoss, Mohammed Al-Saeedi, Pascal Probst, Christoph W. Michalski, Martin Loos, Julian C. Harnoss |
| Résumé: | Introduction Despite advancements in pancreatic surgery, postoperative infections—particularly surgical site infections (SSIs), which occur in 6-17% of cases—continue to be a leading cause of morbidity. Effective perioperative antibiotic prophylaxis is essential, though the optimal regimen remains unclear. Recent studies indicate that broad-spectrum antibiotics may be more effective than cephalosporins; however, agents like piperacillin/tazobactam, despite broader coverage, pose risks of resistance development and increased costs. - Methods and analysis The PERIoperative antibiotic prophylaxis in PANCreatic surgery (PeriPANC) study is a single-centre, prospective, observational study investigating the effectiveness of piperacillin/tazobactam for perioperative antibiotic prophylaxis in pancreatic surgery, compared with a retrospective cohort previously treated with ampicillin/sulbactam. Around 300 adult patients undergoing pancreatic resection will be included. The primary outcome is the incidence of SSI; secondary outcomes include other infectious complications, microbial resistance and healthcare utilisation. Differences between groups will be analysed with analysis of covariance. - Ethics and dissemination The PeriPANC study has been reviewed and approved by the local ethics committee of Heidelberg University Hospital (S-087/2025). As all patients receive standard care and no additional data are collected beyond routine documentation, informed consent is not required. Findings will be disseminated through peer-reviewed publications. The results are expected to inform clinical practice and guideline development in the field of perioperative infection prevention in pancreatic surgery. - Trial registration number German Clinical Trials Register (DRKS): DRKS00036546. |
|---|---|
| Description: | Gesehen am 25.11.2025 |
| Description matérielle: | Online Resource |
| ISSN: | 2044-6055 |
| DOI: | 10.1136/bmjopen-2025-103572 |